[go: up one dir, main page]

Bernieh, 2017 - Google Patents

Application of microsampling methods to cardiovascular medication adherence assessment

Bernieh, 2017

View PDF
Document ID
13476191063353381685
Author
Bernieh D
Publication year

External Links

Snippet

Cardiovascular disease remains the number one killer globally. However, adherence to medication is a major health problem. It has been reported that 50% of cardiovascular patients do not adhere to treatment. This level of nonadherence results in poor health …
Continue reading at core.ac.uk (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/543—Immunoassay; Biospecific binding assay with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/28—Electrolytic cell components
    • G01N27/30—Electrodes, e.g. test electrodes; Half-cells
    • G01N27/327—Biochemical electrodes electrical and mechanical details of in vitro measurements

Similar Documents

Publication Publication Date Title
Jung et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis
Harahap et al. Volumetric absorptive microsampling as a sampling alternative in clinical trials and therapeutic drug monitoring during the COVID-19 pandemic: a review
Tanna et al. Hyphenated mass spectrometry techniques for assessing medication adherence: advantages, challenges, clinical applications and future perspectives
Dasgupta et al. Therapeutic drug monitoring data: a concise guide
Zijp et al. Clinical value of emerging bioanalytical methods for drug measurements: a scoping review of their applicability for medication adherence and therapeutic drug monitoring
Bernieh et al. Quantitative LC–HRMS determination of selected cardiovascular drugs, in dried blood spots, as an indicator of adherence to medication
Frederick Toxicology testing in alternative specimen matrices
Drain et al. Point-of-care and near real-time testing for antiretroviral adherence monitoring to HIV treatment and prevention
Richter et al. Development and application of a LC-HRMS/MS method for analyzing antihypertensive drugs in oral fluid for monitoring drug adherence
Mercolini et al. Current advances in biosampling for therapeutic drug monitoring of psychiatric CNS drugs
Kuwayama et al. Effectiveness of saliva and fingerprints as alternative specimens to urine and blood in forensic drug testing
Scholz et al. A comprehensive multi-analyte method for hair analysis: substance-specific quantification ranges and tool for task-oriented data evaluation
Tanna et al. Analytical chemistry for assessing medication adherence
Müller et al. Dried blood spot sampling for therapeutic drug monitoring: challenges and opportunities
Fu et al. Artificial intelligent olfactory system for the diagnosis of Parkinson’s disease
Skoglund et al. Clinical trial of a new technique for drugs of abuse testing: a new possible sampling technique
Bossi et al. Revolutionizing blood collection: innovations, applications, and the potential of microsampling technologies for monitoring metabolites and lipids
Avataneo et al. A non-invasive method for detection of antihypertensive drugs in biological fluids: the salivary therapeutic drug monitoring
van Wijk et al. A liquid-chromatography high-resolution mass spectrometry method for non-FDA approved benzodiazepines
Methling et al. Hair analysis of antidepressants and antipsychotics—Overview of quantitative data
Kumar et al. Use of spectroscopic methods and their clinical applications in drug abuse: A review
Osman et al. Review of the methods to measure non-adherence with a focus on chemical adherence testing
Chernonosov The use of dried blood spots for the quantification of antihypertensive drugs
Sharma et al. Measurement tools and utility of hair analysis for screening adherence to antihypertensive medication
Shitole et al. Technological advancement in dry blood matrix microsampling and its clinical relevance in quantitative drug analysis